home All News open_in_new Full Article

Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT

CT-155 showed a reduction in experiential negative symptoms as an adjunct to standard of care antipsychotic therapy from baseline to week 16, as measured by CAINS-MAP. CT-155 is an investigational prescription digital therapeutic being evaluated to target negative symptoms of schizophrenia in a registrational randomized clinical trial.1,2 Often underappreciated and less recognized, negative symptoms impact […]


today 8 d. ago attach_file Economics

attach_file Other
attach_file Economics
attach_file Events
attach_file Events
attach_file Other
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Other
attach_file Transport
attach_file Events
attach_file Events
attach_file Other


ID: 3508241162
Add Watch Country

arrow_drop_down